Search results for "Subcutaneous"

showing 10 items of 162 documents

Bioavailability of nevirapine in rats after oral and subcutaneous administration, in vivo absorption from gastrointestinal segments and effect of bil…

2011

Abstract Nevirapine is a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type-1. The usual dosing regimen is 200 mg twice/day. Reducing the dosing frequency would significantly improve treatment adherence and quality of life of patients. To study new forms of administration, it is necessary to do pre-clinical studies and know the absorption characteristics of nevirapine in laboratory animals. However, there are no studies about its bioavailability in rats and hardly any about its pharmacokinetic. The objectives of this study were to describe the pharmacokinetics of nevirapine in rats after intravenous, oral and subcutaneous administration, to assess its absorp…

Malemedicine.medical_specialtyNevirapineDuodenumInjections SubcutaneousPharmaceutical ScienceAdministration OralBiological AvailabilityIleumAbsorption (skin)PharmacologyGastroenterologyIntestinal absorptionPharmacokineticsSpecies SpecificityOral administrationInternal medicinemedicineAnimalsBileHumansNevirapineRats Wistarbusiness.industrydigestive oral and skin physiologyBioavailabilityRatsGastrointestinal Tractmedicine.anatomical_structureIntestinal AbsorptionInjections IntravenousDuodenumReverse Transcriptase Inhibitorsbusinessmedicine.drugInternational journal of pharmaceutics
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

Aspirin treatment improves bladder function after outlet obstruction in rabbits.

2001

Abstract Objectives. To examine whether bladder smooth muscle dysfunction after outlet obstruction could be altered by treatment with aspirin. Long-term outlet obstruction causes contractile and metabolic dysfunction of the bladder in vivo and in vitro. The evidence is growing that a decrease in bladder perfusion is an important cause of this phenomenon. The platelet aggregation inhibitor, acetylsalicylic acid (aspirin), has been used to improve perfusion of the heart for decades. Methods. Ten male New Zealand white rabbits were obstructed for 4 weeks. Five rabbits received no further treatment (Obs), and 5 rabbits received 2 mg/kg/day aspirin (Obs+aspirin), administered by an osmotic pump …

Malemedicine.medical_specialtyUrologyInjections SubcutaneousUrinary BladderUrologyConnective tissueStimulationurologic and male genital diseasesBladder outlet obstructionBleeding timeInternal medicinemedicineAnimalsDrug ImplantsAspirinmedicine.diagnostic_testAspirinbusiness.industryMuscle SmoothOrgan SizeUrinary Bladder Neck ObstructionNeck of urinary bladderEndocrinologymedicine.anatomical_structurePlatelet aggregation inhibitorRabbitsbusinessPerfusionmedicine.drugUrology
researchProduct

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

2010

SummaryThis trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40 mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embol…

Malemedicine.medical_specialtymedicine.drug_classArthroplasty Replacement HipInjections SubcutaneousAdministration OralLow molecular weight heparinHemorrhage030226 pharmacology & pharmacyAntithrombinsDabigatranlaw.invention03 medical and health sciencesPostoperative Complicationsoral thromboprophylaxis dabigatran flebography0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansMedicineEnoxaparinAgedVenous Thrombosisbusiness.industryAnticoagulantAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseSurvival AnalysisDabigatranSurgeryPulmonary embolismVenous thrombosisDirect thrombin inhibitorAnesthesiabeta-AlanineBenzimidazolesFemalebusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Histological and histomorphometrical analysis of a silica matrix embedded nanocrystalline hydroxyapatite bone substitute using the subcutaneous impla…

2010

The clinical suitability of a bone substitute material is determined by the ability to induce a tissue reaction specific to its composition. The aim of this in vivo study was to analyze the tissue reaction to a silica matrix-embedded, nanocrystalline hydroxyapatite bone substitute. The subcutaneous implantation model in Wistar rats was chosen to assess the effect of silica degradation on the vascularization of the biomaterial and its biodegradation within a time period of 6 months. Already at day 10 after implantation, histomorphometrical analysis showed that the vascularization of the implantation bed reached its peak value compared to all other time points. Both vessel density and vascula…

Materials scienceBone substituteBiomedical Engineering2204 Biomedical EngineeringBioengineering610 Medicine & healthBiomaterialsSubcutaneous TissueIn vivoAbsorbable ImplantsMaterials TestingAnimalsRats WistarBone regeneration11077 Center for Applied Biotechnology and Molecular Medicine1502 Bioengineering2502 BiomaterialsBiomaterialSilicon DioxideNanocrystalline materialRatsDrug CombinationsDurapatiteGiant cellSilica matrixBone SubstitutesSubcutaneous implantationNanoparticlesFemaleBiomedical engineeringBiomedical materials (Bristol, England)
researchProduct

Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response.

2012

Mice Inbred BALB CVaccinesGlycosylationGlycosylationMolecular StructureAntigen-antibody reactionsInjections SubcutaneousMucinMucin-1GlycopeptidesSerum Albumin BovineGeneral ChemistryCatalysisGlycopeptideAntigen-Antibody Reactionschemistry.chemical_compoundMiceImmune systemchemistryBiochemistryCell cultureCell Line TumorAnimalsHumansMUC1Angewandte Chemie (International ed. in English)
researchProduct

Contribution of outgrowth endothelial cells from human peripheral blood on in vivo vascularization of bone tissue engineered constructs based on star…

2009

In the present study we assessed the potential of human outgrowth endothelial cells (OEC), a subpopulation within endothelial progenitor cell cultures, to support the vascularization of a complex tissue engineered construct for bone. OEC cultured on starch polycaprolactone fiber meshes (SPCL) in monoculture retained their endothelial functionality and responded to angiogenic stimulation by VEGF (vascular endothelial growth factor) in fibrin gel-assays in vitro. Co-culture of OEC with human primary osteoblasts (pOB) on SPCL, induced an angiogenic activation of OEC towards microvessel-like structures achieved without additional supplementation with angiogenic growth factors. Effects of co-cul…

Mice SCID02 engineering and technologyBone tissueBone tissue engineeringNeovascularizationMicechemistry.chemical_compoundSubcutaneous TissueImplants ExperimentalTissue engineeringOsteogenesisEndothelial progenitor cells0303 health sciencesIn vivo testTissue ScaffoldsbiologyStarch021001 nanoscience & nanotechnology3. Good healthCell biologyVascular endothelial growth factorDrug CombinationsPhenotypemedicine.anatomical_structureMechanics of MaterialsProteoglycansCollagenmedicine.symptom0210 nano-technologyPolyestersBiophysicsNeovascularization PhysiologicBioengineeringEndothelial progenitor cellBone and BonesFibrinBiomaterials03 medical and health sciencesIn vivomedicineAnimalsHumansCell Proliferation030304 developmental biologyMatrigelScience & TechnologyOsteoblastsTissue EngineeringVascularizationEndothelial CellsCoculture TechniquesGene Expression RegulationchemistryCeramics and Compositesbiology.proteinLamininBiomedical engineeringBiomaterials
researchProduct

Assessment of the interaction of Portland cement-based materials with blood and tissue fluids using an animal model

2016

Portland cement used in the construction industry improves its properties when wet. Since most dental materials are used in a moist environment, Portland cement has been developed for use in dentistry. The first generation material is mineral trioxide aggregate (MTA), used in surgical procedures, thus in contact with blood. The aim of this study was to compare the setting of MTA in vitro and in vivo in contact with blood by subcutaneous implantation in rats. The tissue reaction to the material was also investigated. ProRoot MTA (Dentsply) was implanted in the subcutaneous tissues of Sprague-Dawley rats in opposite flanks and left in situ for 3 months. Furthermore the material was also store…

Mineral trioxide aggregatePortland cementDental materials0206 medical engineeringDentistry02 engineering and technologyArticlelaw.inventionEndodontics03 medical and health sciences0302 clinical medicineAnimal modellawIn vivoProroot mtaMultidisciplinarybusiness.industryChemistryHistologyPortland cement -- Analysis030206 dentistryChronic inflammatory reaction020601 biomedical engineeringPortland cementSubcutaneous implantationCalcium silicatesbusinessBiomedical materialsBiomedical engineeringScientific Reports
researchProduct

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patien…

2015

OBJECTIVE: To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053).METHODS: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg every-2-weeks (Q2W) (1-mL subcutaneous injection via pre-filled pen); add-on ezetimibe 10 mg/day; or double-dose rosuvastatin. Patients had cardiovascular disease (CVD) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (1.8 mmol/L) or CVD risk factors and LDL-C ≥100 mg/dL (2.6 mmol/L). In the alirocumab group, dose was blindly increased at Week 12 to 150 mg Q2W (also 1-mL volume) in patients not achieving their LDL-C target. Primary endpoi…

Monoclonal antibodymedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaInjections SubcutaneousHypercholesterolemiaUrology030204 cardiovascular system & hematologyPharmacologyAntibodies Monoclonal Humanizedlaw.inventionPCSK9Rosuvastatin03 medical and health sciences0302 clinical medicineDouble-Blind MethodEzetimibeRandomized controlled triallawmedicineClinical endpointHumansLow-density lipoprotein cholesterolRosuvastatinIn patient030212 general & internal medicineRosuvastatin CalciumAlirocumab; Ezetimibe; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Rosuvastatin; Cardiology and Cardiovascular MedicineRetrospective StudiesAlirocumabDose-Response Relationship Drugbusiness.industryAnticholesteremic AgentsPCSK9Antibodies Monoclonalnutritional and metabolic diseasesCholesterol LDLEzetimibeRosuvastatin CalciumTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineFollow-Up StudiesAlirocumabmedicine.drugAtherosclerosis
researchProduct